OncLive TV

Jerry L​e Pow Spivak, MD, discusses diagnosing essential thrombocythemia.

Lan G. Coffman, MD, PhD, discusses the role of targeted therapy in triple-negative breast cancer.

Timothy M. Pawlik, MD, PhD, MPH, discusses advances in the management of patients with metastatic colorectal cancer with liver metastases.

Raajit K. Rampal, MD, PhD, discusses the evolution of prognostic models in essential thrombocythemia.

Hussein A. Tawbi, MD, PhD, discusses future research efforts in melanoma.

Brad S. Kahl, MD, discusses remaining challenges with CAR T-cell therapy in diffuse large B-cell lymphoma.

Ursula A. Matulonis, MD, discusses the need to improve responses to immunotherapy among patients with recurrent gynecologic cancers.

Yi Lin, MD, PhD, discusses​s updated results of the phase 1 CRB-401 study in relapsed/refractory multiple myeloma.

Robert Zeiser, MD, discusses results of the REACH3 trial in chronic graft-versus-host disease.

Brian T. Hill, MD, PhD, discusses ​the safety profiles of BTK inhibitors in mantle cell lymphoma.

Michael Schweizer, MD, discusses the role of olaparib in patients with non–BRCA-mutant metastatic castration-resistant prostate cancer.

Christian Buske, MD, discusses ​the results of the iNNOVATE trial in Waldenström macroglobulinemia.

Ruben A. Mesa, MD, discusses the anticipated utility of momelotinib in myelofibrosis.

Preetesh Jain, MD, PhD, discusses the rationale to evaluate ibrutinib in combination with rituximab in mantle cell lymphoma.

Peter Voorhees, MD, a multiple myeloma specialist at Levine Cancer Institute, of Atrium Health, discusses updated results of the GRIFFIN trial in multiple myeloma.

Corey S. Cutler, MD, MPH, FRCPC, discusses ​the results of the ROCKstar study in chronic graft-versus-host disease.

Spyridoula Vasileiou, PhD, discusses the potential role of ALVR109​, a SARS-CoV-2 virus–specific T-cell therapy, for the treatment of coronavirus disease 2019.

Srdan Verstovsek, MD, PhD, discusses findings from the PV-AIM trial in polycythemia vera.

William G. Wierda, MD, PhD, discusses results from the CAPTIVATE trial in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Firas El Chaer, MD, discusses the role of next-generation sequencing (NGS) in myeloproliferative neoplasms.

Erlene Seymour, MD, discusses investigational BTK inhibitors in chronic lymphocytic leukemia.

Jia Ruan, MD, PhD, discusses future research with CAR T-cell therapy in mantle cell lymphoma.

Nirav N. Shah, MD, associate professor​, Medical College of Wisconsin, discusses ​the dosing of tandem receptor CAR T-cell therapy in B-cell malignancies.

Prithviraj Bose, MD, discusses risk factors associated with essential thrombocythemia.

Debra Patt, MD, PhD, MBA, ​breast medical oncologist​, vice president of Texas Oncology, highlight​s the role of sacituzumab govitecan-hziy in triple-negative breast cancer.

Joshua Brody, MD, discusses the expanding role of venetoclax in mantle cell lymphoma.

Suthee Rapisuwon, MD, discusses the frontline treatment of acral and mucosal melanoma.

Allison Winter, MD, discusses emerging agents in chronic lymphocytic leukemia.

Daniel P. Petrylak, MD, discusses the role of docetaxel based on the results of the ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Alison R. Sehgal, MD, discusses key targetable alterations in acute myeloid leukemia.